Abstract

Alveolar rhabdomyosarcoma (ARMS) is an aggressive primitive tumor with limited differentiation of rhabdomyoblasts. Primarily, it occurs in children and teens under 15 years of age in the head and neck region (in 40 % of cases). In patients older than 19-20 years, ARMS is significantly less common and is localized primarily on the limbs, while head and neck region is affected in about 24 % of all cases, involvement of the orbit in the tumor process is very rare. ARMS progression in adults is more aggressive than in children, and prognosis is more unfavorable due to development of regional and distant metastases at the time of diagnosis. Hence, selection of antitumor therapy is limited to drug treatment. Use of multimodal approach to therapy allows to improve treatment outcomes and increase quality of life in patients with ARMS.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.